The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments explode. Choosing between AbbVie Inc (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) requires weighing diversification against specialized growth.
AbbVie is a broad biopharmaceutical giant with a diverse lineup of immunology and oncology drugs. Novo Nordisk focus is narrower, leading the world in metabolic health through its diabetes and obesity therapies. Both are high-profile pharmaceutical stocks, but they offer very different risk and reward profiles for retail investors.
AbbVie functions as a diversified pharmaceutical company that develops and sells therapies for immunology, oncology, and aesthetics. Its primary customers include hospitals, government agencies, and specialty pharmacies, though its U.S. sales are concentrated among three major wholesale distributors. McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Inc (NYSE:COR) represent significant distribution partners, and customer concentration like this adds a layer of risk to the business.
In FY 2025, revenue reached $61.2 billion, representing revenue growth of just about 8.7% compared to the previous year. The company reported net income of $4.2 billion for the same period. This resulted in a net margin around 7%, which measures how much of each dollar in revenue is kept as profit after all expenses are paid.